Citations

Clear

959 citation(s) found for "Service, F J".

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Miguel, Jesús F. San , Paiva, Bruno , Kumar, Shaji , Mateos, María‐Victoria , Usmani, Saad Z. , Cook, Gordon , Cavo, Michèle , Quach, Hang , Ukropec, Jon, Ramaswami, Priya, Pei, Huiling , Qi, Mia, Sun, Steven , Wang, Jianping , Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Rampelbergh, Rian Van , Kudva, Anupa, Kobos, Rachel, Qi, Ming , San-Miguel, Jesus , Paiva, Bruno , Kumar, Shaji K , Mateos, María-Victoria , Quach, Hang , Cook, Gordon , Usmani, Saad , Avet‐Loiseau, Hervé , Dimopoulos, Meletios Α. , Facon, Thierry T.F. , Touzeau, Cyrille , Jakubowiak, Andrzej , Bahlis, Nizar Jacques

Mayo Clinic

Blood | July 16, 2021 | Volume: 139 | Issue: 4 | Pages: 492-501

10.1182/blood.2020010439 | PMID 34269818 Get It

Abstract In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10−5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).
Management of Congenital Long-QT Syndrome: Commentary From the Experts
Kaufman, Elizabeth S. , Eckhardt, Lee L. , Ackerman, Michael J. , Aziz, Peter F. , Behr, Elijah R. , Cerrone, Marina , Chung, Mina K. , Cutler, Michael J. , Etheridge, Susan P. , Krahn, Andrew D. , Lubitz, Steven A. , Priori, Silvia G. , Roberts, Jason D. , Roden, Dan M. , Schulze‐Bahr, Eric , Shoemaker, M. Benjamin , Sy, Raymond W. , Towbin, Jeffrey A. , Wilde, Arthur A.M. , Zaręba, Wojciech , Behr, Elijah Raphael , Eckhardt, Lee L , Krahn, Andrew D , Lubitz, Steven A , Cerrone, Marina , Zareba, Wojciech , Priori, Silvia , Pérez, Marco , Roden, Dan M. , Schwartz, Peter J. , Shimizu, Wataru , Viskin, Sami

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 9, 2021 | Volume: 14 | Issue: 7 | Pages: No page available

10.1161/circep.120.009726 | PMID 34238011 Get It

While published guidelines are useful in the care of patients with long-QT syndrome, it can be difficult to decide how to apply the guidelines to individual patients, particularly those with intermediate risk. We explored the diversity of opinion among 24 clinicians with expertise in long-QT syndrome. Experts from various regions and institutions were presented with 4 challenging clinical scenarios and asked to provide commentary emphasizing why they would make their treatment recommendations. All 24 authors were asked to vote on case-specific questions so as to demonstrate the degree of consensus or divergence of opinion. Of 24 authors, 23 voted and 1 abstained. Details of voting results with commentary are presented. There was consensus on several key points, particularly on the importance of the diagnostic evaluation and of β-blocker use. There was diversity of opinion about the appropriate use of other therapeutic measures in intermediate-risk individuals. Significant gaps in knowledge were identified.
The safety of COVID‐19 convalescent plasma donation: A multi‐institutional donor hemovigilance study
Cho, Joseph H. , Rajbhandary, Srijana , Buren, Nancy L. Van , Al‐Ghafry, Maha , Fridey, Joy, Dy, Beth A., Ziman, Alyssa , Schreiber, George B. , Gammon, Richard R. , Reik, Rita A., Stubbs, James R. , Buskirk, Camille M. van , Kamel, Hany , Townsend, Mary , Zeller, Michelle P. , Gottschall, Jerome L. , van Buren, Nancy L , Fung, Mark K , Ziman, Alyssa , Schreiber, George B , Gammon, Richard R , Stubbs, James R , van Buskirk, Camille M, Townsend, Mary J

Mayo Clinic

Transfusion | July 6, 2021 | Volume: 61 | Issue: 9 | Pages: 2668-2676

10.1111/trf.16572 | PMID 34227689 Get It

AbstractBackgroundAlthough the safety and therapeutic efficacy of COVID‐19 convalescent plasma (CCP) has been extensively evaluated, the safety of CCP donation has not been explored in a multi‐institutional context.Study design and methodsNine blood collection organizations (BCOs) participated in a multi‐institutional donor hemovigilance effort to assess the safety of CCP donation. Donor adverse events (DAEs) were defined according to the Standard for Surveillance of Complications Related to Blood Donation, and severity was assessed using the severity grading tool. Multivariate analysis was performed to determine attributes associated with DAE severity.ResultsThe overall DAE rate was 37.7 per 1000 donations. Repeat apheresis and apheresis‐naïve donors experienced adverse event rates of 19.9 and 49.8 per 1000 donations, respectively. Female donors contributed 51.9% of CCP donations with a DAE rate of 49.4 per 1000 donations. The DAE rate for male donors was 27.4 per 1000 donations. Vasovagal reactions accounted for over half of all reported DAEs (51.1%). After adjustment, volume of CCP donated was associated with vasovagal reaction severity (odds ratio [OR] 6.5, 95% confidence interval [CI] 2.5–17.1). Donor age and donation history were also associated with DAE severity. Considerable differences in DAE types and rates were observed across the participating BCOs despite the use of standardized hemovigilance definitions.ConclusionThe safety of CCP donation appears comparable to that of conventional apheresis plasma donation with similar associated risk factors for DAE types and severity.
Abstract 18543: Whole Exome Sequencing in Sudden Infant Death Syndrome Identifies a High Proportion of Putative Pathogenic and Functionally Significant Rare Variants Related to Inherited Cardiac Conditions
Wong, Leonie C.H., Tester, David J. , Evans, Margaret J., Platt, Craig, Jeffrey, Iona, Ackerman, Michael J. , Simpson, Michael A. , FitzPatrick, David R , Tfelt‐Hansen, Jacob , Bevan, Steve , Ware, James S. , Fleming, Peter , Cohen, Marta Cecilia , Behr, Elijah Raphael

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.18543 Get It

Introduction: Sudden Infant Death Syndrome (SIDS) is defined as the sudden death of an infant which remains unexplained after comprehensive clinical and pathological assessment. Prior studies have implicated inherited cardiac conditions (ICC). Hypothesis: Whole exome sequencing will identify a significant burden of putative pathogenic (PP) and rare functionally significant (RFS) cardiac genetic variants in SIDS. Methods: 96 SIDS cases with complete phenotypic data were selected from 434 cases. Prone sleeping position was excluded to enrich for genetic risk. Genomic DNA underwent target enrichment using Agilent SureSelect Human All Exon v5 kit and sequencing on Illumina HiSeq. Reads were aligned to GRCh37 reference genome with Novoalign and variants called with SAMtools. Principal component analysis identified 82 cases of North European (NE) ancestry. Variants were annotated with Annovar and compared to control data from a local exome database, 1000 Genomes and ESP. Analysis focused on 83 known ICC susceptibility genes (27 channelopathy-associated [CH]; 56 cardiomyopathy-associated [CM]). PP was defined as ultra rare nonsense or frameshift mutations or other variants previously reported as disease-associated and absent in controls. RFS was defined as variants with abnormal functional characterization and <0.5% prevalence in controls. Results: 20/82 cases (24%) carried at least 1 PP/RFS variant: 12 CH variants in 9 genes (AKAP9, ANK2, CACNB2, CAV3, KCNE2, RYR2, SCN5A, SNTA1, TRDN) in 13 cases; 7 CM variants in 5 genes (ABCC9, ACTN2, CSRP3, TCAP, TTN) in 8 cases. Variants were most commonly identified in the 3-6 months age group (p=0.009). There were no other significant phenotypic differences between variant-positive and negative cases (Table 1). Conclusions: There was an 11% yield of PP variants in non-prone sleeping SIDS cases of NE ancestry, with an additional 13% hosting RFS variants. These may provide a potential substrate in the pathophysiology of SIDS.
Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating—a step in the right direction for targeted treatment? Authors' reply
Nelson, Alfred D. , Black, Christopher J. , Houghton, Lesley A. , Lugo‐Fagundo, Nahyr , Lacy, Brian E. , Ford, Alexander C. , Lugo-Fagundo, Nahyr Sofía, Houghton, L A , Ford, Alexander C , Black, Christopher J

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 25, 2021 | Volume: 54 | Issue: 2 | Pages: 198-199

10.1111/apt.16443 | PMID 34170542 Get It

LINKED CONTENTThis article is linked to Nelson et al and Vasant papers. To view these articles, visit https://doi.org/10.1111/apt.16437 and https://doi.org/10.1111/apt.16440
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening
Requena, David , Ramos‐Espiritu, Lavoisier , Ng, Denise , Bhola, Patrick , Jong, Ype P. de , Wang, Ruisi , Narayan, Nicole J.C., Shebl, Bassem , Michailidis, Eleftherios , Vercauteren, Koen , Hurley, Arlene , Farber, Benjamin A. , Hammond, William J. , Saltsman, James A. , Weinberg, Ethan M. , Glickman, J. Fraser , Lyons, Barbara A. , Ellison, Jessica, Schadde, Erik , Hertl, Martin, Leiting, Jennifer L. , Truty, Mark J. , Smoot, Rory L. , Tierney, Faith, Kato, Tomoaki , Wendel, Hans‐Guido , Rice, Charles M. , Letai, Anthony , Simon, Sanford M. , Requena, David , de Jong, Ype P , Michailidis, Eleftherios , Vercauteren, Koen O A , Hurley, Arlene M , Farber, Benjamin A , Hammond, William J , Glickman, J Fraser , Leiting, Jennifer L , Smoot, Rory L , LaQuaglia, Michael P , Simon, Sanford M , Weinberg, Ethan M , Lalazar, Gadi , Levin, Solomon , Kabbani, Mohammad , LaQuaglia, Michael P. , Coffino, Philip , Torbenson, Michael , Ortiz, Michael V.

Mayo Clinic

Cancer Discovery | June 14, 2021 | Volume: 11 | Issue: 10 | Pages: 2544-2563

10.1158/2159-8290.cd-20-0872 | PMID 34127480 Get It

Abstract To repurpose therapeutics for fibrolamellar carcinoma (FLC), we developed and validated patient-derived xenografts (PDX) from surgical resections. Most agents used clinically and inhibitors of oncogenes overexpressed in FLC showed little efficacy on PDX. A high-throughput functional drug screen found primary and metastatic FLC were vulnerable to clinically available inhibitors of TOPO1 and HDAC and to napabucasin. Napabucasin's efficacy was mediated through reactive oxygen species and inhibition of translation initiation, and specific inhibition of eIF4A was effective. The sensitivity of each PDX line inversely correlated with expression of the antiapoptotic protein Bcl-xL, and inhibition of Bcl-xL synergized with other drugs. Screening directly on cells dissociated from patient resections validated these results. This demonstrates that a direct functional screen on patient tumors provides therapeutically informative data within a clinically useful time frame. Identifying these novel therapeutic targets and combination therapies is an urgent need, as effective therapeutics for FLC are currently unavailable. Significance: Therapeutics informed by genomics have not yielded effective therapies for FLC. A functional screen identified TOPO1, HDAC inhibitors, and napabucasin as efficacious and synergistic with inhibition of Bcl-xL. Validation on cells dissociated directly from patient tumors demonstrates the ability for functional precision medicine in a solid tumor. This article is highlighted in the In This Issue feature, p. 2355
Systematic review and network meta‐analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation
Nelson, Alfred D. , Black, Christopher J. , Houghton, Lesley A. , Lugo‐Fagundo, Nahyr , Lacy, Brian E. , Ford, Alexander C. , Lugo-Fagundo, Nahyr Sofía, Houghton, L A , Ford, Alexander C , Black, Christopher J

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 11, 2021 | Volume: 54 | Issue: 2 | Pages: 98-108

10.1111/apt.16437 | PMID 34114657 Get It

SummaryBackgroundAlthough bloating is a highly prevalent and troublesome symptom in irritable bowel syndrome with constipation (IBS‐C), treatment is empirical with no specific guidelines for its management.AimTo conduct a pairwise and network meta‐analysis, using a frequentist approach, of Food and Drug Administration‐licensed drugs for IBS‐C comparing their efficacy for abdominal bloating as a specific endpoint.MethodsWe searched the medical literature through December 2020 to identify randomised controlled trials (RCTs) in IBS‐C, with abdominal bloating reported as a dichotomous assessment. Efficacy of each drug was reported as a pooled relative risk (RR) with 95% confidence intervals (CIs) to summarise effect of each comparison tested. Treatments were ranked according to their P‐score.ResultsWe identified 13 eligible RCTs, containing 10 091 patients. Linaclotide 290 µg o.d., lubiprostone 8 µg b.d., tenapanor 50 mg b.d. and tegaserod 6 mg b.d. were all superior to placebo for abdominal bloating in patients with IBS‐C, in both pairwise and the network meta‐analyses. Linaclotide demonstrated the greatest improvement in abdominal bloating in both pairwise and network meta‐analysis (RR of failure to achieve an improvement in abdominal bloating = 0.78; 95% CI 0.74‐0.83, number needed to treat = 7, P‐score 0.97). Indirect comparison revealed no significant differences between individual drugs.ConclusionsWe found all licensed drugs for IBS‐C to be superior to placebo for abdominal bloating. Linaclotide appeared to be the most efficacious at relieving abdominal bloating. Further research is needed to assess long‐term efficacy of these agents and to better understand the precise mechanism of improving bloating.
Multi-Laboratory Evaluation of an Automated Microbial Detection/Identification System
Smith, P. B., Gavan, T L, Isenberg, Henry D., Sonnenwirth, Alex C., Taylor, Welton I., Washington, John A., Balows, Albert

Mayo Clinic

Journal of Clinical Microbiology | June 2, 2021 | Volume: 8 | Issue: 6 | Pages: 657-666

10.1128/jcm.8.6.657-666.1978 | PMID 370141 Get It

An automated and computerized system (Automicrobic System [AMS]) for the detection of frequently encountered bacteria in clinical urine specimens was tested in a collaborative study among six laboratories. The sensitivity, specificity, reliability, and reproducibility of the AMS were determined, and the system was compared with conventional detection and identification systems. In this study, pure cultures and mixtures of pure cultures were used to simulate clinical urine specimens. With pure cultures, the sensitivity of the AMS in identifying the nine groups of organisms most commonly found in urine averaged 92.8%. The specificity averaged 99.4%, and the reliability of a positive result averaged 92.1%. The latter value was strongly influenced by a relatively high occurrence of false positive Escherichia coli results. The AMS was capable of detecting growth of most organisms, including those which it was not designed to identify. However, it identified some of these incorrectly as common urinary tract flora. Reproducibility of results, both within laboratories and among different laboratories, was high. Fast-growing organisms, such as E. coli and Klebsiella/Enterobacter species, were detected often at cell populations well below the AMS enumeration threshold of 70,000/ml. In mixed culture studies, high levels of sensitivity and specificity were maintained but when Serratia species were present in mixtures with other organisms, there was often a false positive report of E. coli. The overall performance of the AMS was considered satisfactory under the test conditions used.
Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.
Martin, Thomas , Usmani, Saad Zafar, Vij, Ravi , Tian, Hong , Valluri, Satish , Marino, Jennifer , Jackson, Carolyn C. , Banerjee, Arnob , Schecter, Jordan M. , Kumar, Shaji , Usmani, Saad Z. , Usmani, Saad , Costa, Luciano J. , Lin, Yi , Chhabra, Saurabh , Jagannath, Sundar , Callander, Natalie S. , Berdeja, Jesús G. , Kang, Yubin , Kansagra, Ankit , Hari, Parameswaran

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 8030-8030

10.1200/jco.2021.39.15_suppl.8030 Get It

8030 Background: CARTITUDE-1 is a single arm study of Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) anti-BCMA CAR-T cell therapy in US patients (pts) with relapsed multiple myeloma (RRMM) refractory to both IMiD and proteasome inhibitor (PI) or with at least 3 prior lines of therapy and previously exposed to anti-CD38 monoclonal antibody (MoAb). While recently reported efficacy results of cilta-cel were encouraging, it is unknown how they compare with similar pts receiving conventional (non CAR-T) treatment. Methods: We utilized a contemporary US-based dataset of pts with MM refractory to anti-CD38 MoAb (MAMMOTH) to identify pts who would meet eligibility for CARTITUDE-1 and who received conventional therapy. We analyzed the intent-to-treat population (ITT) in CARTITUDE-1, defined as pts who underwent apheresis (N=113) and a modified ITT population (mITT) defined as subset of pts who received cilta-cel at the RP2D (N=97). From the MAMMOTH dataset, we identified a population corresponding to CARTITUDE-1 ITT (N=190) and a mITT population, pts without death or progression within 47 days (median time between apheresis and cilta-cel infusion) from onset of therapy (N=122). We calculated propensity scores (PS) with demographics, N of prior therapies, cytogenetics and refractoriness to MM agents as covariates. An analyst blinded to outcomes performed nearest neighbor 1:1 PS matching. We analyzed overall response rate (ORR), progression-free (PFS) and overall survival (OS) for ITT and mITT in CARTITUDE-1 vs matching MAMMOTH cohorts. Results: Ninety-five ITT (75 received bridging therapy, 82 received cilta-cel) and 69 mITT (54 received bridging) CARTITUDE-1 pts matched MAMMOTH pts (Table). Among the pts in the MAMMOTH ITT cohort 34% received pomalidomide, 24% anti-CD38 MoAb, 19% carfilzomib and 35% cytotoxic chemotherapy in next therapy. ORR in the ITT cohorts was higher in CARTITUDE-1 (84% vs. 28%). Compared to their MAMMOTH counterparts, pts in CARTITUDE-1 ITT cohort had improved PFS (12 mo. 73% vs. 12%) and OS (12 mo. 83% vs 39%). Between the mITT cohorts, CARTITUDE-1 pts had superior ORR (96% vs. 30%), PFS (12 mo 79% vs. 15%) and OS (12 mo. 88% vs. 41%). Conclusions: In pts with RRMM beyond therapy with IMID, PI, and anti-CD38 MoAb, treatment with cilta-cel is associated with higher response rate and superior PFS and OS when compared to conventional treatment.[Table: see text]
Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.
Usmani, Saad Zafar, Madduri, Deepu , Yeh, Tzu‐Min, Olyslager, Yunsi, Banerjee, Arnob , Jackson, Carolyn C. , Allred, Alicia J., Zudaire, Enrique, Deraedt, William , Wu, Xiaoling , Carrasco-Alfonso, Marlene J., Martin, Thomas G. , Usmani, Saad Z. , Usmani, Saad , Berdeja, Jesús G. , Jakubowiak, Andrzej , Agha, Mounzer , Cohen, Adam D. , Hari, Parameswaran , Akram, Muhammad , Lin, Yi , Jagannath, Sundar

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 8005-8005

10.1200/jco.2021.39.15_suppl.8005 Get It

8005 Background: CARTITUDE-1 (NCT03548207) is a phase 1b/2 study evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two BCMA–targeting single-domain antibodies, in patients (pts) with R/R MM. Here, we report updated results in pts with a longer duration (median 12.4 months) of follow-up. Methods: Eligible pts had MM and received ≥3 prior regimens or were double refractory to a proteasome inhibitor (PI) and immunomodulatory drug (IMiD), and had received a PI, IMiD, and anti-CD38 antibody. After apheresis, bridging therapy was permitted. Pts received a single cilta-cel infusion (target dose: 0.75×106 CAR+ viable T cells/kg; range 0.5-1.0×106) 5–7 days (d) after lymphodepletion (300 mg/m2 cyclophosphamide, 30 mg/m2 fludarabine daily for 3 d). The primary objectives were to characterize cilta-cel safety, confirm the recommended phase 2 dose (RP2D; phase 1b), and evaluate efficacy (phase 2). Cytokine release syndrome (CRS) was graded by Lee et al (Blood 2014) and neurotoxicity by CTCAE, v5.0 (in phase 1b). CRS and ICANS were graded by ASTCT criteria (in phase 2). Here, Lee et al and CTCAE v5.0 were mapped to ASTCT for CRS and ICANS, respectively. Results: As of Sept 1, 2020, 97 pts with a median of 6 prior lines received cilta-cel. Overall response rate per independent review committee (primary endpoint) was 97% (95% CI, 91–99), with 67% achieving stringent complete response (sCR). Median time to first response was 1 month (range, 1–9), and median time to CR or better was 2 months (range, 1–15). Responses deepened over time, and median duration of response was not reached. Of 57 pts evaluable for minimal residual disease (MRD) assessment, 93% were MRD-negative at 10-5. The 12-month progression-free survival (PFS) and overall survival rates (95% CI) were 77% (66–84) and 89% (80–94), respectively; median PFS was not reached. Grade 3/4 hematologic AEs ≥20% included neutropenia (95%), anemia (68%), leukopenia (61%), thrombocytopenia (60%), and lymphopenia (50%). CRS occurred in 95% of pts (4% grade 3/4), with median time to onset of 7 d (range, 1–12), and median duration of 4 d (range, 1–14, excluding 1 pt with 97-d duration). CRS resolved in all but one with grade 5 CRS/haemophagocytic lymphohistiocytosis. CAR T-cell neurotoxicity occurred in 21% of pts (grade ≥3, 10%). Fourteen deaths occurred during the study after cilta-cel infusion: none within the first 30 days, 2 within 100 days; and 12 more than 100 days post infusion, of which 5 were due to disease progression, and 4 due to treatment-related AEs. Conclusions: A single infusion of cilta-cel yielded early, deep, and durable responses in heavily pretreated pts with MM, with a manageable safety profile at the RP2D. Cilta-cel is under further investigation in other MM populations in earlier lines of therapy and in outpatient settings. Clinical trial information: NCT03548207.